SatRx → Partners

Our partners


ChemRar High-Tech Center is a unique pharma and biotechnology conglomerate built in Russian Federation by highly innovative life science R&D organizations, discovering, developing and commercializing novel drugs for partners in Russia and worldwide. The mission of the company is to develop and commercialise existing drugs on the basis of novel “post-genomic” technologies used for treatment of cancer, infectious, cardiovascular and central nervous system (CNS) diseases as well metabolic disorders.


One of the oldest pharmaceutical company and one of the biggest in the word with more than 160 years history. The company manufactures products for a wide range of customers. Diversified product portfolio includes biologic and small molecule medicines and vaccines for humans and animals, as well as products for a healthy diet and a number of well-known throughout the world of non-prescription drugs. Pfizer invests more than U.S. $ 7 billion in research and development of new medicines. Under the agreement, Pfizer has granted worldwide exclusive rights (except China) to SatRx for development, manufacturing, regulatory submission, and commercialization of the DPPIV molecule alone and in combination with certain classes of molecules. If approved and commercialized, Pfizer will receive royalties and milestone payments from SatRx.


The University of California, San Diego is one of the top-ranked public research universities in the nation. The University воркситх with the Medical Center of San Diego and works together with a number of regional centers of excellence such as: the Salk Institute, Sanford-Burnham Medical Research Institute, The Scripps Research Institute. In the University worked eight Nobel Prize winners, the holder of three U.S. National Science Medal and a Pulitzer Prize.


A leading pharmaceutical company in Italy, Dompé develops innovative treatment solutions for diseases that have a high social impact and are often orphan diseases. Based in Italy with HQ in Milan, Dompé focuses on Research in areas where there are still unmet treatment needs such as juvenile diabetes, ophthalmology and oncology. For more information:


ChemDiv, Inc. is a fully integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The Company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the World. Company engages pharmaceutical and biotech partners by offering 'one stop' drug discovery and development services based on a project-, FTE- and risk sharing collaborative modes.


"Northern" BioPharmCluster at Moscow Institute of Physics and Technology (BPCN@MIPT) is a conglomerate of leading enterprises of pharmaceutical and medical industry, research institutes and medical institutions, small innovative companies on the base of the Moscow Institute of Physics and Technology. BPCN@MIPT is established as part of implementation of the Strategy for development of pharmaceutical industry of the Russian Federation for the period until 2020 (“Pharma2020”). The main mission of BPCN@MIPT is to transfer the Moscow Region on innovative model of development of pharmaceutical and medical industry with cumulative potential and competence of organizations – participants of the Cluster. The main approach of the cluster development is to establish the zone of small innovative enterprises and corporative laboratories in Life Sciences on the base of MIPT.


IPHARMA LLC is a clinical CRO at ChemRar group of companies focusing on all-phase clinical trials of innovative drugs from translational research to marketing authorization, as well as biosimilar, bioequivalence and post-approval studies. IPHARMA aims to contribute to bringing novel treatments to patients by providing outstanding clinical research services to biotech and pharmaceutical companies.


ChemDiv Research Institute (CDRI) - is a contract research organization focused on pre-clinical and clinical R&D from target identification to clinical candidate nomination and Proof of Concept in human. CDRI sees its mission in enabling discovery and development of innovative therapies for unmet needs utilizing highest expertise and innovation potential of Russian scientists with integrated external R&D solutions of Discovery outSource TM platforms. Since 1990 we offer R&D services in CNS, oncology, inflammation, CV, metabolic disease area to our pharma and biotech partners. Discovery outSource TM platform solutions cover the complete range of disciplines from identification of a biological target (protein expression, assay development etc.); to clinical drug candidates (ADME/DMPK, toxicity, safety, animal models, drug formulation etc.); to drug development (Phase I to Phase IV).